Mirikizumab (Omvoh™) for ulcerative colitis

Alexander Hammerhøj; Theresa Louise Boye; Ebbe Langholz; Ole Haagen Nielsen

doi:10.1016/j.tips.2024.01.001

Mirikizumab (Omvoh™) for ulcerative colitis

Alexander Hammerhøj, Theresa Louise Boye, Ebbe Langholz, Ole Haagen Nielsen

Research output: Contribution to journal › Journal article › Research › peer-review

Abstract

STRUCTURE: Mirikizumab is a humanized IgG4-variant monoclonal antibody consisting of two heavy-chain and two light-chain subunits. Mirikizumab binds with high affinity to the p19 subunit (α subunit) of the heterodimeric interleukin-23 (IL-23).

Original language	English
Journal	Trends in Pharmacological Sciences
Volume	45
Issue number	3
Pages (from-to)	281-282
Number of pages	2
ISSN	0165-6147
DOIs	https://doi.org/10.1016/j.tips.2024.01.001
Publication status	Published - 2024

Access to Document

10.1016/j.tips.2024.01.001

Cite this

@article{3ffc8410b2c043c4bd8379ddb0befeee,

title = "Mirikizumab (Omvoh{\texttrademark}) for ulcerative colitis",

abstract = "STRUCTURE: Mirikizumab is a humanized IgG4-variant monoclonal antibody consisting of two heavy-chain and two light-chain subunits. Mirikizumab binds with high affinity to the p19 subunit (α subunit) of the heterodimeric interleukin-23 (IL-23).",

author = "Alexander Hammerh{\o}j and Boye, {Theresa Louise} and Ebbe Langholz and Nielsen, {Ole Haagen}",

year = "2024",

doi = "10.1016/j.tips.2024.01.001",

language = "English",

volume = "45",

pages = "281--282",

journal = "Trends in Pharmacological Sciences",

issn = "0165-6147",

publisher = "Elsevier Ltd. * Trends Journals",

number = "3",

}

TY - JOUR

T1 - Mirikizumab (Omvoh™) for ulcerative colitis

AU - Hammerhøj, Alexander

AU - Boye, Theresa Louise

AU - Langholz, Ebbe

AU - Nielsen, Ole Haagen

PY - 2024

Y1 - 2024

N2 - STRUCTURE: Mirikizumab is a humanized IgG4-variant monoclonal antibody consisting of two heavy-chain and two light-chain subunits. Mirikizumab binds with high affinity to the p19 subunit (α subunit) of the heterodimeric interleukin-23 (IL-23).

AB - STRUCTURE: Mirikizumab is a humanized IgG4-variant monoclonal antibody consisting of two heavy-chain and two light-chain subunits. Mirikizumab binds with high affinity to the p19 subunit (α subunit) of the heterodimeric interleukin-23 (IL-23).

U2 - 10.1016/j.tips.2024.01.001

DO - 10.1016/j.tips.2024.01.001

M3 - Journal article

C2 - 38262797

VL - 45

SP - 281

EP - 282

JO - Trends in Pharmacological Sciences

JF - Trends in Pharmacological Sciences

SN - 0165-6147

IS - 3

ER -